Point-of-Care Infectious Disease Diagnostics & Testing Market Size, Share, Growth, and Industry Analysis, By Type (HIV POC, Clostridium difficile POC, HBV POC, Pneumonia or Streptococcus associated infections, Respiratory syncytial virus (RSV) POC, HPV POC, Influenza/Flu POC, Other Infectious Disease POC), By Application (Hospitals, Clinics, Home, Assisted Living Healthcare Facilities, Laboratories, Others), Regional Insights and Forecast to 2034

Point-of-Care Infectious Disease Diagnostics & Testing Market Overview

The Point-of-Care Infectious Disease Diagnostics & Testing - Market size was valued at USD 2238.3 million in 2025 and is expected to reach USD 3283.88 million by 2034, growing at a CAGR of 4.4% from 2025 to 2034.

The Point-of-Care Infectious Disease Diagnostics & Testing Market supports over 4.5 billion infectious disease tests annually, with point-of-care (POC) platforms accounting for nearly 38% of decentralized diagnostic volumes across 190+ countries. More than 60% of acute respiratory infection cases are initially screened using rapid antigen or molecular POC assays delivering results within 15–30 minutes. Globally, over 1.3 million healthcare facilities utilize at least 1 POC infectious disease testing device, while cartridge-based molecular systems represent 42% of installed POC platforms. The Point-of-Care Infectious Disease Diagnostics & Testing Market Size is influenced by 296 million hepatitis B cases and 39 million HIV cases worldwide, driving continuous demand for rapid, near-patient testing solutions.

In the United States, over 70 million rapid infectious disease POC tests are performed annually across 6,000+ hospitals and 10,000+ urgent care centers. Approximately 65% of influenza tests are conducted using CLIA-waived POC platforms with turnaround times under 20 minutes. The U.S. reports nearly 1.2 million people living with HIV and 2.4 million hepatitis C cases, with over 55% of screenings performed outside central laboratories. More than 50% of emergency departments deploy multiplex PCR-based POC systems capable of detecting 15–25 respiratory pathogens simultaneously. The Point-of-Care Infectious Disease Diagnostics & Testing Market Share in the U.S. is supported by 35,000+ retail clinics offering rapid antigen or molecular infectious disease screening.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver:65% rapid testing preference, 58% decentralized diagnostics adoption, 72% emergency care reliance, 48% molecular POC penetration, 60% infectious case screening coverage.
• Major Market Restraint:34% cost sensitivity, 29% reimbursement limitations, 26% device maintenance burden, 22% quality variability concerns, 18% regulatory approval delays.
• Emerging Trends:45% multiplex assay integration, 39% home-based testing adoption, 31% digital connectivity expansion, 28% AI-supported result interpretation, 24% biosensor innovation.
• Regional Leadership:North America 36%, Europe 28%, Asia-Pacific 24%, Middle East & Africa 7%, Latin America 5%.
• Competitive Landscape:Top 5 companies 57%, cartridge-based systems 42%, antigen tests 38%, molecular POC 48%, strategic collaborations 21%.
• Market Segmentation:HIV POC 18%, Influenza POC 22%, HPV POC 14%, RSV POC 12%, HBV POC 11%, C. difficile POC 8%, Pneumonia/Strep 9%, Others 6%.
• Recent Development:Multiplex panel upgrades 27%, CLIA-waived approvals 23%, digital integration 19%, portable device launches 21%, home-test authorizations 17%.

Point-of-Care Infectious Disease Diagnostics & Testing Market Latest Trends

Point-of-Care Infectious Disease Diagnostics & Testing Market Trends highlight the expansion of multiplex molecular panels capable of identifying 20+ pathogens in a single 30-minute run, reducing diagnostic time by 40% compared to centralized PCR testing. Over 45% of tertiary hospitals have adopted cartridge-based molecular POC systems with sensitivity levels above 95% for respiratory pathogens. Rapid antigen tests account for nearly 38% of global POC volumes, with specificity exceeding 90% in influenza and RSV detection. Home-based infectious disease POC kits increased distribution by 39% between 2023 and 2025, particularly for HIV and HPV screening.

Digital connectivity integration enables 31% of POC devices to transmit results directly into electronic health record systems within 60 seconds. Battery-operated handheld analyzers weighing less than 2 kilograms now represent 25% of newly installed systems in rural settings. The Point-of-Care Infectious Disease Diagnostics & Testing Market Outlook indicates over 50% of urgent care visits for respiratory symptoms utilize on-site POC assays. Biosensor-based microfluidic chips reduce sample volume requirements to less than 100 microliters, enhancing usability in pediatric cases representing 20% of total respiratory infections annually.

Point-of-Care Infectious Disease Diagnostics & Testing Market Dynamics

DRIVER

Increasing global burden of infectious diseases and demand for rapid diagnosis.

Globally, infectious diseases account for nearly 20% of total deaths annually, with lower respiratory infections responsible for over 2.6 million fatalities. Rapid POC diagnostics reduce clinical decision time by 30–50%, enabling immediate antimicrobial intervention in 70% of suspected bacterial infections. Influenza affects approximately 1 billion individuals annually, while RSV leads to 33 million lower respiratory tract infections in children under 5. HIV testing coverage reached 76% of affected populations, with 55% conducted through decentralized POC systems. Emergency department visits for infectious symptoms increased by 18% over 3 years, accelerating Point-of-Care Infectious Disease Diagnostics & Testing Market Growth through high-volume, rapid-result testing demand.

RESTRAINT

Regulatory complexity and quality control variability.

Over 25% of manufacturers report approval timelines exceeding 12 months for new POC assays. Quality control inconsistencies affect 22% of small-scale facilities lacking standardized calibration protocols. False-negative rates in antigen tests may range from 5% to 12% depending on viral load levels. Approximately 29% of healthcare providers cite reimbursement restrictions as limiting adoption of advanced molecular POC platforms. Device downtime averaging 6% annually can reduce throughput by 15% in high-volume centers. These operational barriers impact broader Point-of-Care Infectious Disease Diagnostics & Testing Industry Analysis metrics, especially in emerging economies with fewer than 2 diagnostic devices per 10,000 population.

OPPORTUNITY

Expansion of home-based and decentralized healthcare.

Home-based infectious disease testing increased by 39% from 2023 to 2025, with self-administered HIV and influenza kits achieving over 92% user accuracy. Rural healthcare coverage improved by 14% with portable POC devices requiring less than 1 hour training for operation. Telehealth consultations linked to POC test results rose by 28%, enabling digital prescriptions within 24 hours. Approximately 48% of new infectious disease screening programs integrate mobile diagnostic units capable of processing 50–100 tests daily. The Point-of-Care Infectious Disease Diagnostics & Testing Market Opportunities expand as 60% of global primary care facilities lack on-site central laboratory access, increasing demand for compact, cartridge-based systems.

CHALLENGE

Supply chain disruptions and raw material dependency.

Over 33% of manufacturers experienced reagent shortages during peak infectious outbreaks. Semiconductor component delays extended device production timelines by 4–6 months in 2023. Approximately 21% of POC device production relies on cross-border supply chains involving more than 3 countries. Cartridge-based systems require single-use plastics, contributing to 18% higher consumable dependency. Transportation delays exceeding 10 days can disrupt distribution to 15% of remote clinics. These constraints create volatility in Point-of-Care Infectious Disease Diagnostics & Testing Market Forecast planning, especially in regions with import dependency rates above 70%.

Segmentation Analysis

The Point-of-Care Infectious Disease Diagnostics & Testing Market Segmentation is divided by type and application, with influenza/flu POC holding 22% share and HIV POC 18%. Hospitals account for 44% of usage, clinics 21%, home settings 16%, assisted living facilities 8%, laboratories 7%, and others 4%. Molecular POC platforms represent 48% of device installations, while antigen-based assays represent 38%, reflecting balanced technology adoption across care settings.

By Type

HIV POC:HIV POC accounts for 18% of test volumes, with over 150 million rapid HIV tests conducted annually worldwide. Approximately 76% of individuals living with HIV are aware of their status, with 55% diagnosed through POC platforms. Rapid antibody tests deliver results within 20 minutes with sensitivity above 99% in established infections. Over 60% of sub-Saharan screening programs utilize finger-prick POC kits costing under 1 hour per session for 10–20 patients. Self-testing adoption increased by 32% between 2023 and 2025.

Clostridium difficile POC:C. difficile POC represents 8% share, with 500,000 infections annually in the U.S. alone. Rapid antigen and molecular assays detect toxins A and B within 30 minutes. Hospital-acquired infection rates of 4–8 cases per 10,000 patient-days support POC adoption in inpatient units. Molecular assays demonstrate sensitivity exceeding 92%.

HBV POC:HBV POC contributes 11%, targeting 296 million chronic hepatitis B cases globally. Rapid HBsAg tests provide results in 15–30 minutes with specificity above 98%. Approximately 70% of low-income screening programs rely on POC kits due to limited central lab access.

Pneumonia or Streptococcus Associated Infections:This segment accounts for 9%, with streptococcal pharyngitis affecting 616 million people annually. Rapid strep tests provide 10-minute results with sensitivity near 85–95%. Pneumonia-related POC panels detect 15+ pathogens simultaneously.

Respiratory Syncytial Virus (RSV) POC:RSV POC holds 12%, addressing 33 million pediatric infections yearly. Antigen tests produce results in under 15 minutes with specificity above 90%. Pediatric hospitalizations account for 3.6 million cases annually.

HPV POC:HPV POC represents 14%, supporting screening of 660 million women globally aged 15–49. Rapid HPV DNA tests identify high-risk strains in under 1 hour with sensitivity exceeding 90%. Vaccination coverage stands near 20–30% in many regions, increasing screening demand.

Influenza/Flu POC:Influenza POC leads with 22%, reflecting 1 billion seasonal infections annually. Rapid antigen tests deliver 15-minute results, while molecular POC achieves 95% sensitivity. Approximately 65% of outpatient flu cases use POC diagnostics.

Other Infectious Disease POC:Other infectious disease POC accounts for 6%, including dengue with 390 million infections annually and malaria with 249 million cases. Rapid diagnostic tests detect malaria antigens in 15 minutes with sensitivity above 95%.

By Application

Hospitals:Hospitals represent 44% of POC usage, with over 70% of emergency departments deploying multiplex respiratory panels. Average hospital volumes exceed 20,000 infectious POC tests annually. On-site testing reduces patient isolation time by 25%.

Clinics:Clinics hold 21% share, performing 5,000–15,000 POC tests annually per facility. Rapid influenza and strep tests constitute 60% of clinic-based POC volumes. Same-day diagnosis improves prescription accuracy by 30%.

Home:Home settings account for 16%, driven by 39% growth in self-testing kits. HIV and influenza home kits achieve over 90% accuracy. Digital result sharing occurs in 28% of cases.

Assisted Living Healthcare Facilities:Assisted living facilities represent 8%, where residents aged over 65 account for 70% of RSV and influenza-related complications. On-site POC reduces hospitalization rates by 18%.

Laboratories:Laboratories account for 7%, integrating POC analyzers for rapid triage. Satellite labs process 100–300 rapid tests daily, complementing central PCR capacity.

Others:Other applications represent 4%, including mobile clinics conducting 50–200 tests per day in outbreak zones.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

• North America leads with 36% market share, supported by 70% rapid testing penetration.
• Europe accounts for 28%, driven by 60% influenza POC adoption.
• Asia-Pacific holds 24%, reflecting 14% increase in rural diagnostic access.
• Middle East & Africa contribute 7%, with 55% HIV screening via POC.
• Latin America captures 5%, supported by 48% decentralized testing expansion.

North America

North America commands 36% market share, with over 80% of hospitals utilizing CLIA-waived POC systems. The region conducts more than 100 million influenza and RSV POC tests annually. Approximately 65% of primary care visits for respiratory symptoms include rapid antigen or molecular assays. Over 50% of retail pharmacies provide on-site infectious disease POC testing. Digital connectivity integration exceeds 40%, allowing automated reporting within 1 minute. HIV awareness testing coverage reaches 85%, with 60% performed via rapid POC kits.

Europe

Europe holds 28% share, with over 70% vaccination-linked screening programs incorporating POC diagnostics. Influenza affects 10–30% of the population annually, supporting 60% POC adoption in outpatient clinics. Approximately 45% of emergency departments use multiplex PCR panels. HPV POC screening coverage reaches 65% in organized cervical programs.

Asia-Pacific

Asia-Pacific represents 24%, with over 3 billion population driving infectious testing volumes. Rural healthcare expansion increased POC installations by 14% over 5 years. Dengue affects 100 million symptomatic individuals annually, supporting rapid test demand. Approximately 50% of hepatitis B screenings use rapid POC kits.

Middle East & Africa

Middle East & Africa account for 7%, with HIV prevalence exceeding 20% in select countries. Over 55% of HIV screenings utilize POC platforms. Malaria cases total 249 million globally, with a large portion in Africa using rapid diagnostic tests. Mobile clinics increase rural coverage by 18%.

List of Top Point-of-Care Infectious Disease Diagnostics & Testing Companies

• Abbott – holding approximately 19% global market share in rapid antigen and molecular POC infectious testing platforms.
• Roche – accounting for nearly 16% market share in cartridge-based molecular point-of-care infectious disease diagnostics.
• Thermo Fisher Scientific Inc
• Siemens Healthineers
• BD & Company
• Chembio Diagnostics Inc.
• Trinity Biotech
• Cardinal Health
• Quest Diagnostics Inc
• Bio-Rad Labs Inc
• bioMérieux SA
• Sight Diagnostics Ltd.
• Gene POC
• Trivitron Healthcare
• OJ-Bio Ltd., Ortho-Clinical Diagnostics

Investment Analysis and Opportunities

Investments in Point-of-Care Infectious Disease Diagnostics & Testing Market infrastructure increased by 24% between 2022 and 2025, with over 600 hospitals upgrading to multiplex molecular POC platforms. Government infectious surveillance budgets allocate up to 15% toward rapid testing procurement. Venture capital funding for biosensor startups rose by 21%, supporting development of microfluidic chips detecting 10–20 pathogens simultaneously. Approximately 48% of new primary healthcare centers in emerging economies include at least 1 POC infectious analyzer. Mobile diagnostic vans equipped with 3–5 POC devices process 100 tests daily in outbreak zones. Public-private partnerships expanded by 18%, targeting screening coverage of 80% for high-risk populations. Digital health integration, adopted by 31% of new installations, supports automated data reporting within 60 seconds, enhancing epidemiological surveillance accuracy by 25%.

New Product Development

Between 2023 and 2025, over 40 new POC infectious assays received regulatory authorization globally. Multiplex respiratory panels detecting 20 pathogens achieved sensitivity above 95% and specificity above 97%. Handheld analyzers weighing under 1.5 kilograms increased portability by 30%. Cartridge shelf life extended to 18–24 months, reducing wastage by 12%. AI-enabled readers interpret lateral flow assays with 98% image recognition accuracy. Battery-operated devices with 8-hour runtime improved field deployment by 22%. Smartphone-linked POC kits allow 28% of users to share results electronically within 2 minutes. Microfluidic chip innovations reduced sample volume requirements to 50 microliters, improving pediatric usability by 20%. These advancements align with Point-of-Care Infectious Disease Diagnostics & Testing Market Forecast expansion across decentralized healthcare ecosystems.

Five Recent Developments (2023–2025)

1. Abbott expanded rapid influenza and RSV dual testing capacity by 25%, improving throughput to 200 tests per hour.
2. Roche launched a multiplex PCR POC panel detecting 20 respiratory pathogens within 30 minutes with 96% sensitivity.
3. Siemens Healthineers enhanced cartridge automation reducing manual steps by 35%.
4. BD introduced a portable molecular POC device weighing 1.2 kilograms with 8-hour battery support.
5. bioMérieux SA upgraded infectious disease panels improving specificity to 98% across 15 pathogens.

Report Coverage of Point-of-Care Infectious Disease Diagnostics & Testing Market

The Point-of-Care Infectious Disease Diagnostics & Testing Market Report covers analysis across 190+ countries, evaluating over 50 infectious disease indications and 8 major product categories. The report assesses installation base exceeding 1.3 million POC devices and analyzes test volumes surpassing 4.5 billion annually. It includes segmentation by 8 test types and 6 application settings, quantifying market share distribution of 36% in North America, 28% in Europe, 24% in Asia-Pacific, and 7% in Middle East & Africa. The Point-of-Care Infectious Disease Diagnostics & Testing Market Research Report reviews sensitivity benchmarks above 95% for molecular platforms and 90% for antigen tests. It evaluates 40+ recent product launches between 2023 and 2025, installation growth rates above 20% in rural healthcare facilities, and digital integration penetration of 31%, delivering comprehensive Point-of-Care Infectious Disease Diagnostics & Testing Market Insights for B2B stakeholders.